[{"AccountsPayableCurrent_0_Q2_USD":3159000.0,"OperatingLeaseRightOfUseAsset_0_Q2_USD":6959000.0,"OperatingLeaseLiabilityNoncurrent_0_Q2_USD":6224000.0,"OperatingLeaseLiabilityCurrent_0_Q2_USD":930000.0,"OperatingIncomeLoss_2_Q2_USD":-43118000.0,"OperatingIncomeLoss_1_Q2_USD":-23603000.0,"OperatingExpenses_2_Q2_USD":43118000.0,"OperatingExpenses_1_Q2_USD":23603000.0,"NonoperatingIncomeExpense_2_Q2_USD":7360000.0,"NonoperatingIncomeExpense_1_Q2_USD":3953000.0,"OtherAccruedLiabilitiesCurrent_0_Q2_USD":190000.0,"NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1_2_Q2_USD":39000.0,"NetIncomeLoss_1_Q2_USD":-19650000.0,"NetCashProvidedByUsedInOperatingActivities_2_Q2_USD":-37280000.0,"NetCashProvidedByUsedInInvestingActivities_2_Q2_USD":32524000.0,"NetCashProvidedByUsedInFinancingActivities_2_Q2_USD":671000.0,"MarketableSecuritiesRealizedGainLoss_2_Q2_USD":-120000.0,"LiabilitiesNoncurrent_0_Q2_USD":6224000.0,"LiabilitiesCurrent_0_Q2_USD":10114000.0,"LiabilitiesAndStockholdersEquity_0_Q2_USD":243810000.0,"LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_0_Q2_USD":737000.0,"NetIncomeLoss_2_Q2_USD":-35758000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_0_Q2_USD":1291000.0,"OtherAssetsNoncurrent_0_Q2_USD":193000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_2_Q2_USD":16000.0,"StockIssuedDuringPeriodValueEmployeeBenefitPlan_1_Q2_USD":63000.0,"StockholdersEquity_0_Q2_USD":227472000.0,"RetainedEarningsAccumulatedDeficit_0_Q2_USD":-203595000.0,"ResearchAndDevelopmentExpense_2_Q2_USD":31215000.0,"ResearchAndDevelopmentExpense_1_Q2_USD":17546000.0,"PropertyPlantAndEquipmentNet_0_Q2_USD":2180000.0,"ProfitLoss_2_Q2_USD":-35758000.0,"ProceedsFromStockPlans_2_Q2_USD":671000.0,"ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities_2_Q2_USD":84862000.0,"OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax_1_Q2_USD":-33000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q2_USD":7266000.0,"PaymentsToAcquireAvailableForSaleSecuritiesDebt_2_Q2_USD":51695000.0,"OtherNonoperatingIncomeExpense_2_Q2_USD":7127000.0,"OtherNonoperatingIncomeExpense_1_Q2_USD":3943000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_2_Q2_USD":-424000.0,"OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_1_Q2_USD":-295000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_2_Q2_USD":-120000.0,"OtherComprehensiveIncomeLossReclassificationAdjustmentFromAOCIForSaleOfSecuritiesNetOfTax_1_Q2_USD":-97000.0,"OtherComprehensiveIncomeLossNetOfTax_2_Q2_USD":-288000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q2_USD":-231000.0,"PaymentsToAcquirePropertyPlantAndEquipment_2_Q2_USD":643000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_1_Q2_shares":24439623.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearThree_0_Q2_USD":1321000.0,"LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_0_Q2_USD":1417000.0,"CommitmentsAndContingencies_0_Q2_USD":null,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_2_Q2_USD":-4101000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_0_Q2_USD":46491000.0,"CashAndCashEquivalentsFairValueDisclosure_0_Q2_USD":13180000.0,"CashAndCashEquivalentsAtCarryingValue_0_Q2_USD":46491000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q2_USD":163322000.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q2_USD":163322000.0,"AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_0_Q2_USD":108594000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q2_USD":163825000.0,"CommonStockParOrStatedValuePerShare_0_Q2_USD":0.001,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q2_USD":504000.0,"AssetsCurrent_0_Q2_USD":234478000.0,"Assets_0_Q2_USD":243810000.0,"AmortizationOfDebtDiscountPremium_2_Q2_USD":1424000.0,"AllocatedShareBasedCompensationExpense_2_Q2_USD":5655000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q2_USD":2860000.0,"AdditionalPaidInCapitalCommonStock_0_Q2_USD":432763000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q2_USD":-1720000.0,"AccruedProfessionalFeesCurrent_0_Q2_USD":649000.0,"AccruedLiabilitiesCurrent_0_Q2_USD":6025000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q2_USD":1000.0,"LesseeOperatingLeaseLiabilityPaymentsDueYearFour_0_Q2_USD":1352000.0,"CommonStockSharesAuthorized_0_Q2_shares":100000000.0,"CommonStockSharesOutstanding_0_Q2_shares":24443432.0,"LesseeOperatingLeaseLiabilityPaymentsDue_0_Q2_USD":9451000.0,"InvestmentIncomeInterest_2_Q2_USD":564000.0,"InvestmentIncomeInterest_1_Q2_USD":290000.0,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2_Q2_USD":2419000.0,"IncreaseDecreaseInAccruedLiabilities_2_Q2_USD":-784000.0,"IncreaseDecreaseInAccountsPayable_2_Q2_USD":1163000.0,"GeneralAndAdministrativeExpense_2_Q2_USD":11903000.0,"GeneralAndAdministrativeExpense_1_Q2_USD":6057000.0,"ForeignCurrencyTransactionGainLossRealized_2_Q2_USD":-266000.0,"CommonStockSharesIssued_0_Q2_shares":24443432.0,"ForeignCurrencyTransactionGainLossBeforeTax_2_Q2_USD":-331000.0,"EmployeeRelatedLiabilitiesCurrent_0_Q2_USD":2401000.0,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations_2_Q2_USD":-16000.0,"EarningsPerShareBasicAndDiluted_2_Q2_USD":-1.46,"EarningsPerShareBasicAndDiluted_1_Q2_USD":-0.8,"DepreciationDepletionAndAmortization_2_Q2_USD":259000.0,"DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_0_Q2_USD":0.0,"ComprehensiveIncomeNetOfTax_2_Q2_USD":-36046000.0,"ComprehensiveIncomeNetOfTax_1_Q2_USD":-19881000.0,"CommonStockValue_0_Q2_USD":24000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q2_USD":-280000.0,"WeightedAverageNumberOfShareOutstandingBasicAndDiluted_2_Q2_shares":24434852.0,"Ticker":"KALV","CIK":"1348911","name":"KALVISTA PHARMACEUTICALS, INC.","OfficialName":"KalVista Pharmaceuticals Inc. Common Stock","form":"10-Q","period":"20211031","fy":"2022.0","fp":"Q2","qtrs":"0","uom":"USD","footnote":"nan","Market Cap":"339433230.0","Country":"United Kingdom","Sector":"Health Care","Industry":"Biotechnology: Pharmaceutical Preparations","Market":"NASDAQ","SP500":"nan","filed":"20211209"}]